Premarket buying is lifting many COVID-19 vaccine players after IMV (NASDAQ:IMV) announced Health Canada sign-off on a Phase 1 study of its candidate DPX-COVID-19, expected to launch this summer. Shares are up a healthy 153% premarket on robust volume.
Selected tickers: Vaxart (NASDAQ:VXRT) (+12%), Dynavax (NASDAQ:DVAX) (adjuvant news) (+7%), Novavax (NASDAQ:NVAX) (+4%), iBio (NYSEMKT:IBIO) (+1%), GlaxoSmithKline (NYSE:GSK) (+1%), Moderna (NASDAQ:MRNA) (+5%), Inovio Pharmaceuticals (NASDAQ:INO) (+3%), Soligenix (NASDAQ:SNGX) (+8%), Altimmune (NASDAQ:ALT) (+9%), Vir Biotechnology (NASDAQ:VIR) (+2%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.